Former Pfizer Headquarters Renovation Halted After Buckling, Mayor Says, as Midtown Building Conversion Faces New Delays

Construction at the former Pfizer headquarters in Midtown Manhattan was halted Tuesday after structural concerns emerged during a conversion project, according to reporting that described crumbling floors and other issues at the building. The episode adds a new operational disruption to a redevelopment plan that had been underway for years, even as Pfizer’s corporate footprint in New York has long since shifted.

The building, located near Grand Central Terminal, is being converted into a luxury rental complex. City officials ordered evacuations after two structural support columns on the 21st floor began to buckle around 8 a.m. local time, with authorities continuing to assess whether the structure would require additional protective measures.

New York City Mayor Zohran Mamdani said at the scene that the building “remains unstable” and that his team observed a continued shift of the structure after crews arrived. He described the situation as “extremely serious” and said the response was unfolding minute by minute as engineers developed plans to shore up the impacted floor.

Fire officials characterized the risk in terms of collapse scenarios. Because the building is made of steel, the fire commissioner said there is only a possibility of a localized collapse rather than a total collapse, according to the reporting. Authorities also indicated they were working on shoring plans and that engineers would enter the building if the affected floor was deemed secure.

While the redevelopment is tied to Pfizer’s former real estate, the company did not appear in the reporting as providing specific updates about the incident. Tuesday’s coverage focused on the city response and the building’s instability during the ongoing renovation, rather than any contemporaneous statement from Pfizer.

Sector context matters because office-to-residential conversions have been common in large cities, but they can be technically complex when retrofitting older buildings for new loads, layouts, and code requirements. For owners and developers, a sudden stop in construction can translate quickly into additional engineering costs, schedule slippage, and uncertainty around how much work must be redone.

What remains unclear from the public reporting is the full scope of the engineering findings, the timeline for resuming construction, and whether further structural repairs will be required beyond shoring the impacted floor. It also was not clear from the available accounts whether any specific contractor work will be restarted immediately after inspections or whether the project could face broader design and permitting changes.

Investors and market watchers may view the incident less as a direct Pfizer operating event and more as a reminder of how real-estate redevelopment risk can surface abruptly. The immediate question going into Wednesday and beyond is what city engineers conclude about the extent of structural damage and what that means for the conversion’s next permitting and construction steps.